SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.38-9.0%Nov 4 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (2818)2/5/2001 3:35:51 PM
From: Jibacoa  Read Replies (1) of 52153
 
NBIX:

Will see if it can find support at the January Ls around 23 3/8 to 24. If that doesn't hold then still there seems to be good support around the 19 to 20 level (From May last year)As you recall the April L was 13.93

They announced last month positive results from safety, pharmacokinetic, and efficacy Phase I and II studies evaluating NBI-34060 for insomnia in approximately 500 patients.

And in December they announced that they had expanded their collaboration with Taisho Pharmaceutical to develop and commercialize Neurocrine's altered peptide ligand (APL) for diabetes in North America and other countries.

The worldwide collaboration is valued at up to $100 million. Neurocrine expects to receive a total of approximately $12 million under the worldwide collaboration.

Bernard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News